

Unilateral synchronous papillary renal neoplasm with reverse polarity and clear cell renal cell carcinoma: a case report with *KRAS* and *PIK3CA* mutations

Hyun Jung Lee

Pusan National University Yangsan Hospital <https://orcid.org/0000-0002-2995-6060>

Dong Hoon Shin (✉ donghshin@chol.com)

Pusan National University Yangsan Hospital

Joon Young Park

Pusan National University Yangsan Hospital

So Young Kim

Pusan National University Yangsan Hospital

Chung Su Hwang

Pusan National University Yangsan Hospital

Jung Hee Lee

Pusan National University Yangsan Hospital

Jee Yeon Kim

Pusan National University Yangsan Hospital

Mee Young Sol

Pusan National University Yangsan Hospital

Jong Kil Nam

Pusan National University Yangsan Hospital

Case Report

Keywords: papillary renal neoplasm with reverse polarity, clear cell renal cell carcinoma, multiple masses, KRAS mutation, PIK3CA mutation

Posted Date: September 2nd, 2020

DOI: <https://doi.org/10.21203/rs.3.rs-67814/v1>

License:   This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Version of Record: A version of this preprint was published at Diagnostic Pathology on October 6th, 2020.
See the published version at <https://doi.org/10.1186/s13000-020-01042-7>.

Abstract

Background

The presence of histologically different neoplasms in the same organ is rare in pathologic practice. We report multiple synchronous masses of clear cell renal cell carcinoma and papillary renal neoplasm with reverse polarity in the same kidney. Herein, we present the first well-explained case with immunohistochemical findings with next-generation sequencing (NGS) analysis.

Case presentation

A 61-year-old man was incidentally found to have a left renal mass on imaging studies performed for workup of left back pain and urine color change for one week. A laparoscopic left radical nephrectomy was performed. Gross examination showed lobulated masses in the upper to mid pole measuring 5.6 × 4.0 × 3.3 cm and 1.1 × 1.0 × 1.0 cm in the lower pole. Microscopic findings revealed these to be two different separate masses of clear cell renal cell carcinoma and papillary renal neoplasm with reverse polarity. NGS analyses revealed *KRAS* gene mutation (c.35G>T/p.G12V in exon 2) in the papillary renal neoplasm with reverse polarity, with an additional *PIK3CA* gene mutation restricted to the clear cell renal cell carcinoma (c.1624G>A/p.E542K in exon 10).

Conclusions

We report here an extraordinarily rare case of a patient diagnosed with multiple synchronous renal tumors of papillary renal neoplasm with reverse polarity and clear cell renal cell carcinoma. We identified simultaneous *KRAS* and *PIK3CA* mutations in two different renal masses in the same kidney for the first time. New pathologic assessment with comparative molecular analysis of mutational profiles may be helpful for tumor studies.

Introduction

Renal cell carcinoma (RCC) is the most common solid tumor of the kidney and accounts for 2–3% of all malignancies in adults [1]. The most common subtypes of RCC are clear cell, papillary, and chromophobe RCC, and they account for approximately 75%, 10%, and 5% of cases, respectively [2]. Since 1997, papillary renal cell carcinoma has been classified into types 1 and 2 based on morphologic findings [3]. Histologically, papillae are lined by cuboidal cells with scant basophilic cytoplasm on the fibrovascular cores in type I, whose nuclei are usually arranged in a single layer with a low International Society of Urological Pathology (ISUP) grade. In contrast, type II is defined by nuclear pseudostratification, higher ISUP grades, and abundant eosinophilic cytoplasm. Type I has a better prognosis compared with type II. Most recently, 18 cases of papillary renal neoplasm with reverse polarity (PRNRP) were described by Al-Obaidy et al [4]. PRNRP is histologically characterized by thin branching papillae, or rarely, predominant tubules covered by bland oncocytic cells with apical low-ISUP-grade nuclei.

There are a few studies that define bilateral synchronous malignant renal tumors [5, 6] and coexisting benign and malignant tumors in the same kidney [7]. Clear cell RCC and PRNRP arising within the same kidney have not been reported yet in the literature. The presence of histologically different neoplasms in the same organ is rare in pathologic practice. We report multiple synchronous masses of clear cell RCC and PRNRP in the same kidney. Herein, we present the first well-explained case with immunohistochemical findings with next generation sequencing (NGS) analysis of multiple synchronous renal masses. We also reviewed multiple synchronous renal masses in Pusan National University Yangsan Hospital between March 2010 and January 2020.

Materials And Methods

Paraffin sections were prepared (2- μ m thickness) and stained using routine methods on VENTANA (Roche, Basel, Switzerland) and BOND-MAX (Leica Biosystems, Buffalo Grove, IL) autostainers with the following antibodies: AMACR (13H4, α -methylacylcoenzyme A racemase; Agilent Technologies, Santa Clara, CA), CD10 (clone 56C6, Leica Biosystems), cytokeratin 7 (CK7; clone OV-TL 12/30, Leica Biosystems), high-molecular-weight (HMW) keratin (clone 34 β E12, Agilent Technologies), TFE3 (MRQ-37, Cell Marque; Rocklin, CA), E-cadherin (clone 4A2C7; Invitrogen, Carlsbad, CA), CAIX (clone ab15086; Abcam, Cambridge, United Kingdom). Stained slides were scored for the presence and distribution of positive immunostaining.

DNA libraries were prepared using the NGeneBio library prep kit (NGeneBio, Seoul, Korea), enriched for 120-kb fragments, and sequenced with a paired-end 300-bp (150 bp each) protocol using a MiSeq platform (Illumina, San Diego, CA). Targeted sequencing raw data was obtained in FASTAQ format. Raw reads were aligned against the reference human genome assembly (GRCh37/hg19) using NGeneAnalysis v1.4.4.0 software (NGeneBio). A minimum coverage of 20 reads per base-pair was subsequently used for variant calling. Variants with a variant allele frequency of less than 5% were excluded. Variants outside 10 bases from exon-intron boundaries were also excluded from analysis.

Case Presentation

A 61-year-old man was incidentally found to have a left renal mass on imaging studies performed for workup of left back pain and urine color change for one week. A computed tomographic imaging scan of the kidneys revealed an enhancing mass with central necrosis and a sub-centimeter-sized hypodense nodule. A laparoscopic left radical nephrectomy was performed. Pathologic gross examination showed a vaguely circumscribed lobulated mass in the upper to mid pole measuring 5.6 \times 4.0 \times 3.3 cm.

The cut surface of the mass was bright golden yellow with areas of gray-white fibrosis and hemorrhage (Fig. 1a). Apart from this main mass, a separate small nodule was present in the lower pole, measuring 1.2 \times 1.0 \times 0.6 cm (Fig. 1b). The tumor was confined to the kidney, having no extension into the perinephric adipose tissue, renal sinus, renal pelvis, or Gerota fascia. Hematoxylin and eosin (H&E)-stained sections showed a well-circumscribed neoplasm composed predominantly of solid nests and

lobules of large round cells with relatively monotonous round nuclei showing no mitoses and abundant granular eosinophilic cytoplasm (Fig. 1c and d). The second nodule was well-encapsulated, showing proliferation of delicate fibrovascular cores and variable numbers of macrophages. The papillary fibrovascular cores were thick and hyalinized. The tumors were cuboidal with eosinophilic cytoplasm. The nuclei were low-ISUP-grade nuclei and were arranged linearly and inverted toward the apical surface (Fig. 1e and f). For further evaluation, immunohistochemical stains were performed. The tumor cells were positive for CD10, AMACR, CAIX, and vimentin and negative for CK7, TFE3, and GATA3. The separate small mass was positive for CK7, GATA3, AMACR, and EMA and negative for CD10, vimentin, CAIX, and TFE3 (Fig. 2). GATA3 is usually negative in papillary RCC types I and II [4]. Based on the morphology and immunohistochemical findings, a chromophobe or translocation RCC was excluded. The findings were compatible with clear cell RCC and PRNRP. The tumor in the upper pole was clear cell RCC, with pathologic stage pT1b N0 M0. The histologic grade (World Health Organization [WHO]/ISUP nuclear grade) was 3. The second tumor in the lower pole was PRNRP, its pathologic stage was pT1a N0 M0, and its histologic grade (WHO/ISUP nuclear grade) was 2. Sarcomatoid features and necrosis were absent. There were two separate masses in one kidney. The patient has been alive and well for eight months after surgery.

NGS analysis detected a *KRAS* mutation in the PRNRP in the exon 2-codon 12 junction (c.35 G > T resulting in p.G12V). A *PIK3CA* mutation was detected in the clear cell RCC in the exon 10-codon 542 junction (c.1624 G > A resulting in p.E542K) (Fig. 3).

Discussion

Multiple synchronous renal tumors are rare. This is the first case to present synchronous clear cell RCC and PRNRP in the same kidney. PRNRP was first described by Al-Obaidy et al. in 2019 [4]. This study identified a PRNRP with a *KRAS* mutation and a co-occurring clear cell RCC with a *PIK3CA* mutation for the first time in the literature. The different mutation results of NGS analysis supports the biologically different diagnoses of these two synchronous renal masses.

KRAS mutations are frequently found in adenocarcinomas of the lung, colon, and pancreas [8, 9]. Varied papillary lesions, including intraductal papillary mucinous neoplasms of the pancreas and urothelial papillomas of the bladder, also have frequent *KRAS* mutations [10, 11]. *KRAS* mutations in RCCs are very rare and have only been seen in sporadic reports [12].

PIK3CA mutations are rare in clear cell RCC and are present only in 2–5% of tumors [13, 14]. *PIK3CA* codes for the catalytic subunit of phosphoinositide-3-kinase (PIK3), a key enzyme of the mTOR pathway; therefore, the mTOR inhibitor everolimus may be effective for this type of mutation.

The most common symptoms reported are hematuria in 90% of cases, flank pain in 19%, and mass effect in 14% [15]. Our patient presented with the first two symptoms. Regarding aggressiveness, clear cell RCC presents the greatest malignant potential and a 5-year survival rate of 70%, while papillary and

chromophobe RCCs are associated with less metastatic potential and an overall 5-year survival of 88% and 94% [16].

Radical nephrectomy is considered the standard procedure for treating malignant renal tumors. However, recent studies show that patients with sporadic single or multiple ipsilateral renal tumors may undergo nephron-sparing surgery, with oncologically comparable results with low morbidity and recurrence rates.

Awareness of the coexistence of multiple synchronous tumors of different pathologic neoplasms in the same kidney is important for managing such cases, and nephron-sparing surgery or active surveillance may be warranted for some renal masses [17]. The fact that the pathological concordance rate is as low as 67.3% and the grade concordance rate is 62.5% [18] suggests that if a biopsy is indicated preoperatively, each nodule should be biopsied for diagnosis [19]. Different tumors will have different prognoses and degrees of aggressiveness.

There were seven cases of multiple kidney masses in Pusan National University Yangsan Hospital from March 2010 to January 2020, and Table 1 shows the characteristics of these ipsilateral multiple renal masses according to subtype. Papillary and clear cell RCCs were the most frequent types of multiple renal masses. Two reports of large numbers of patients concluded that 5–6% of multiple ipsilateral renal tumors develop a contralateral metachronous recurrence and this risk is 5 times that of patients with a sporadic single tumor [18, 20]. We suggest that multiple ipsilateral synchronous RCCs of different histologic subtypes need to be followed closely and operations for each mass are necessary. The frequency of clinical multifocality is consistent with reported local recurrence rates following partial nephrectomy. The impact of tumor multifocality on patient survival is controversial; however, each nodule should be evaluated for an accurate prognosis.

Table 1
Patient characteristics of ipsilateral multiple renal masses

Case	Age	Sex	Location	Tumor Size (cm)	TNM	Grade	Histologic subtypes
1	64	M	Right	4.0	pT1aN0M0	2	papillary RCC, type I / metanephric adenoma
2	53	M	Right	5.3	pT1bN0M0	2	clear cell RCC/ clear cell RCC
3	66	F	Right	2.5	pT1aN0M0	2	Clear cell RCC/ clear cell RCC
4	65	M	Left	4.6	pT3aN0M0	2	Clear cell RCC/ clear cell RCC
5	57	M	Right	2.5	pT1aN0M0	3	Clear cell RCC/ clear cell RCC
6	77	M	Right	4.9	pT1bN0M0	3	Clear cell RCC/ clear cell RCC
7	62	M	Left	5.6	pT3aN0M0	3	Clear cell RCC/ Papillary RCC, type II

In summary, we report the first and extremely unusual case of unilateral synchronous PRNRP with a *KRAS* mutation (c.35G > T/p.G12V in exon 2) and clear cell RCC with a *PIK3CA* mutation (c.1624G > A/p.E542K in exon 10).

Abbreviations

NGS: next-generation sequencing; RCC:Renal cell carcinoma; ISUP:International Society of Urological Pathology; PRNRP:papillary renal neoplasm with reverse polarity; HMW:high-molecular-weight; H&E:Hematoxylin and eosin; IGV:Integrative Genomics Viewer

Declarations

Acknowledgements

Not applicable

Author's contributions

The report was designed, written and reviewed by Hyun Jung Lee under the supervision of Dong Hoon Shin, Jee Yeon Kim and Mee Young Sol. All authors contributed to the data collection, data analysis and interpretation. The manuscript was approved by all authors.

Funding

This study was supported by Research institute for Convergence of biomedical science and technology (20-2019-003), Pusan National University Yangsan Hospital.

Availability of data and materials

The dataset supporting the conclusions of this article is included within the article.

Ethics approval and consent to participate

This study was approved by the Institutional Review Board of the Pusan National University Yangsan Hospital (no. 05-2020-173).

Consent for publication

Not applicable

Competing interests

The authors declare no competing interests.

References

1. Siegel RL, Miller KD, Jemal A. Cancer statistics. *CA. Cancer J Clin.* 2016;66:7–30.
2. Cohen HT, McGovern FJ. Renal cell carcinoma. *N Engl J Med.* 2005;353:2477–90.
3. Delahunt B, Eble JN. Papillary renal cell carcinoma: a clinicopathologic and immunohistochemical study of 105 tumors. *Mod Pathol.* 1997;10(6):537–44.
4. Al-Obaidy KI, Eble JN, Cheng L, et al. Papillary renal neoplasm with reverse polarity: a morphologic, immunohistochemical, and molecular study. *Am J Surg Pathol.* 2019;43:1099–111.
5. Patel MI, Simmons R, Kattan MW, Motzer RJ, Reuter VE, Russo P. Long-term follow-up of bilateral sporadic renal tumors. *Urology.* 2003;61:921–5.
6. Klatte T, Wunderlich H, Patard JJ, et al. Clinicopathological features and prognosis of synchronous bilateral renal cell carcinoma: an international multicentre experience. *BJU Int.* 2007;100:21–5.
7. Billings B, Hamrick LC, Bueschen AJ, Kenney PJ. Coexisting angiomyolipoma and renal cell carcinoma in a kidney of an elderly woman: case report and review of the literature. *Scientific World Journal.* 2004;4 supplement 1: 27–30.
8. Eberhard DA, Johnson BE, Amler LC, et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small cell lung cancer treated with chemotherapy alone in combination with erlotinib. *J Clin Oncol.* 2005;23:5900–9.
9. Amado RG, Wolf M, Peeters M, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. *J Clin Oncol.* 2008;26:1626–34.

10. Mohri D, Asaoka Y, Ijichi H, et al. Different subtypes of intraductal papillary mucinous neoplasm in the pancreas have distinct pathways to pancreatic cancer progression. *J Gastroenterol.* 2012;47:203–13.
11. Isharwal S, Hu W, Sarungbam J, et al. Genomic landscape of inverted urothelial papilloma and urothelial papilloma of the bladder. *J Pathol.* 2019;248:260–5.
12. Raspollini MR, Castiglione F, Martignoni G, et al. Multiple and bilateral kidney tumors with clear cells of three different histotypes: a case report with clinicopathologic and molecular study. *APMIS.* 2016;1244:619–23.
13. Creighton CJ, Morgan M, Gunaratne PH, et al. Comprehensive molecular characterization of clear cell renal cell carcinoma. *Nature.* 2013;499:43–9.
14. Sato Y, Toshizato T, Shiraishi Y, et al. Integrated molecular analysis of clear cell renal cell carcinoma. *Nat Genet.* 2013;45:860–7.
15. Benavides-Huerto MA, Chávez-Valencia V, Lagunas-Rangel FA. Synchronous renal neoplasm: clear cell renal cell carcinoma and papillary urothelial carcinoma in the same kidney. *Urol Case Rep.* 2017;11:60–2.
16. Amin MB, Tamboli P, Javidan J, et al. Prognostic impact of histologic subtyping of adult renal epithelial neoplasm-An experience of 405 cases. *Am J Surg Pathol.* 2002;26:281–91.
17. Blute M, Thibault GP, Leibovich BC, Chevillet JC, Lohse CM, Zincke H. Multiple ipsilateral renal tumors discovered at planned nephron sparing surgery: importance of tumor histology and risk of metachronous recurrence. *J Urol.* 2003;170:760–3.
18. Beaugerie A, Audenet F, Verkarre V, et al. Pathological heterogeneity in sporadic synchronous renal tumors: is the histological concordance predictable? *Urol Oncol.* 2018;36:11.e7-12.
19. Alhusban M, Alhamss S, Alzumaili B, Al-Daghmin A. Ipsilateral synchronous clear and papillary renal cell carcinoma: A case report and review of the literature. *Urol Case Rep.* 2017;16:110–3.
20. Minervini A, Serni S, Giubilei G, et al. Multiple ipsilateral renal tumors: retrospective analysis of surgical and oncological results of tumor enucleation vs radical nephrectomy. *Eur J Surg Oncol.* 2009;35:521–6.

Figures




Figure 1

The cut surface of the mass was bright golden yellow with areas of gray-white fibrosis and hemorrhage (a). A separate small nodule was present in the lower pole, measuring 1.2 x 1.0 x 0.6cm (b). Microscopic findings of clear cell renal cell carcinoma (c). High-power view of clear cell renal cell carcinoma (d). Microscopic findings of papillary renal neoplasm with reverse polarity (PRNRP) (e). High-power view of PRNRP (f).




Figure 2

Immunohistochemical stain for CAIX in clear cell renal cell carcinoma shows membranous positivity (a). AMACR shows cytoplasmic positivity in clear cell renal cell carcinoma (b). GATA3 in papillary renal neoplasm with reverse polarity (PRNRP) shows strong nuclear positivity (c). CK7 shows diffuse cytoplasmic positivity in PRNRP (d).




Figure 3

Integrative Genomics Viewer (IGV) snapshot of human KRAS gene location with missense mutation identified in papillary renal neoplasm with reverse polarity. The mutation is clustered in p.Gly12Val (a). IGV snapshot of human PIK3CA gene location with missense mutation identified in clear cell renal cell carcinoma. The mutation is clustered in p.Glu542Lys (b).

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [CAREchecklistEnglish2020.pdf](#)